Author: Ravi Shankar

Net Sales Increased 34%, Driven by Vita Coco Coconut Water Growth of 15%; Organic Net Sales Growth¹ of 18%

Net Income Increased $11 million to $35 million and Non-GAAP Adjusted EBITDA² Increased $21 million to $53 million

Raises Fiscal Year 2026 Guidance for Net Sales to Between $810 Million and $820 Million and Non-GAAP Adjusted EBITDA² to between $170 million and $175 million

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2026.

Third Quarter and Year-to-Date 2026 Highlights Compared to Prior Year Period

• Net sales were $244 million, an increase of $62 million, or 34%, in the third quarter, and $640 million year-to-date, an increase of $158 million, or 33%.
• Organic net sales growth¹ was 18% in the third quarter and 27% year-to-date.
• Vita Coco Coconut Water net sales grew 15% in the third quarter and 24% year-to-date.
• Private Label net sales grew 152% in the third quarter and 85% year-to-date, with the third quarter benefiting from the contribution of Copra, a leading producer of super premium Thai Nam Hom coconut water that was acquired in July 2026.
• Gross profit was $93 million in the third quarter, an increase of $24 million, and $270 million year-to-date, an increase of $92 million.

• Gross margin was 38% of net sales in the third quarter consistent with prior year, and was 42% of net sales year-to-date compared to 37%, with tariff refunds delivering a 240 basis point benefit to gross margin year-to-date.
• Net income was $35 million in the third quarter, compared to $24 million, an increase of $11 million, and $115 million year-to-date, compared to $66 million, an increase of $49 million.

• Net income per diluted share was $0.58 in the third quarter, compared to $0.40, and $1.89 per diluted share year-to-date, compared to $1.10.
• Non-GAAP Adjusted EBITDA² was $53 million in the third quarter, compared to $32 million, an increase of $21 million. Non-GAAP Adjusted EBITDA² was $159 million year-to-date, compared to $84 million, an increase of $75 million.

Michael Kirban, the Company’s Co-Founder and Executive Chairman, stated, “The growth of the coconut water category maintained through the fall, and remains one of the fastest growing beverage categories in our major markets. I am particularly pleased by the strong growth in Europe as we develop the category in key markets, and the continued growth in America, driven by increases in both household penetration and in average consumption per household. This quarter, we were pleased to welcome the Copra team to our family and to start executing our joint plans, which we believe will allow us to compete successfully in the super premium segment. With the investments we are making in our supply chain, and our strong brand performance, I am confident in our plans to maintain our growth into 2027, and our category leadership well into the future.”

Martin Roper, the Company’s Chief Executive Officer, said, “Our strong third quarter net sales growth was driven by robust branded retail growth in all our major markets, and by strong growth in private label shipments, reflecting healthy category growth and the addition of Copra’s super premium products. Excluding the impact of Copra, the underlying 18% organic net sales growth of our business remained very strong, exceeding our expectations. Consumer demand is very healthy, and we are therefore raising our full year Net Sales and Adjusted EBITDA guidance.”

Third Quarter 2026 Consolidated Results

Net sales increased $62 million, or 34%, to $244 million for the third quarter ended September 30, 2026, compared to $182 million in the prior year period. The increase in net sales was driven by case equivalent (“CE”) volume gains of 16% for Vita Coco Coconut Water and 77% for Private Label. Organic net sales growth¹, which is net sales growth excluding the impact of Copra, was 18% for the quarter. Copra net sales primarily impacted Private Label, with Copra branded coconut water and commodity net sales recognized in Other.

Gross profit increased to $93 million, from $69 million in the prior year period driven by higher sales volume, the addition of Copra, and minimal tariffs compared to the prior year period, partially offset by higher domestic logistics costs. Gross margin was 38%, in line with the prior year period, benefitting from minimal tariffs compared to the prior year period, offset by higher domestic logistics costs, and the dilutive impact of Copra.

Selling, general and administrative (“SG&A”) expenses were $47 million, compared to $41 million in the prior year period. The increase was primarily driven by costs related to the acquisition of Copra, amortization expense associated with intangible assets acquired in the Copra acquisition, higher people-related costs reflecting increased headcount and stock-based compensation, as well as higher sales related expenses.

Net income was $35 million, or $0.58 per diluted share, compared to net income of $24 million, or $0.40 per diluted share, in the prior year period. Net income benefited from higher gross profit, partially offset by higher SG&A spending and increased income tax expense.

Non-GAAP Adjusted EBITDA² was $53 million, compared to $32 million in the prior year due to the increased gross profit partially offset by higher SG&A expenses.

Balance Sheet

As of September 30, 2026, the Company’s financial position remained strong with no debt and $152 million in cash and cash equivalents. Cash decreased $45 million from the beginning of the year, and $127 million from end of the second quarter due to net cash used for the acquisition of Copra of $139 million. Our inventory was $111 million, flat to December 31, 2025, with the inclusion of Copra inventory offsetting the inventory draw down from strong year-to-date shipments. Accounts receivable increased to $129 million from $82 million as of prior year end due to strong quarterly sales and the inclusion of Copra.

As of September 30, 2026, the Company had repurchased approximately $86 million of its common stock under its share repurchase program and had $19 million remaining under the existing authorization. During the nine months ended September 30, 2026, the Company repurchased $62 million of its common stock. As of October 22, 2026, the Company has repurchased $94 million of its common stock, and had $11 million remaining of the $105 million authorized amount under the repurchase program.

Fiscal Year 2026 Full Year Outlook³

The Company is increasing its full year 2026 guidance, as follows:

• Net sales expected to be between $810 million and $820 million, driven by low 20s percent growth of Vita Coco Coconut Water, strong Private Label trends and the addition of Copra. (Prior guidance was between $790 million and $805 million, which included the benefit of Copra).
• Gross margin expected to be approximately 40% with benefit relative to prior year from lower tariffs, tariff refunds, and higher pricing partially offset by increased ocean freight, product and other transportation costs, alongside adverse product mix, primarily due to the impact of Copra’s private label business and strong private label trends. (No change from prior guidance). Fourth quarter gross margin expected to be approximately 33% due to increases in cost of goods and no offsetting price actions expected until early 2027.
• Expect to deliver SG&A leverage of approximately 1.5 percentage points of net sales vs. 2025. (Prior guidance was one percentage point).
• Adjusted EBITDA² expected to be in the range of $170 million to $175 million. (Prior guidance was between $154 million and $161 million).

Uncertainty and instability in the current operating environment, geopolitical landscape, and global economies, including the military conflict in Iran and related impacts, changes in tariff rates, natural disasters, associated potential competitive pricing actions, and our own price elasticity could affect this outlook and our future results.

Footnotes

(1)	Organic net sales growth is a supplemental measure of net sales performance that excludes the impact of net sales attributable to the Copra acquisition as set forth in the U.S. GAAP to non-GAAP reconciliation table below.
(2)	Adjusted EBITDA represents earnings before interest, taxes, depreciation, and amortization as adjusted for certain items as set forth in the reconciliation table of U.S. GAAP to non-GAAP information and is a measure calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Non-GAAP Financial Measures herein for further discussion and reconciliation of this measure to GAAP measures.
(3)	GAAP Net income 2026 outlook is not provided due to the inherent difficulty in quantifying certain amounts due to a variety of factors including the unpredictability in the movement in foreign currency rates, as well as future charges or reversals outside of the normal course of business.

Conference Call and Webcast Details

To participate in the live earnings call and question and answer session, please register at https://register-conf.media-server.com/register/BIb7dfca7ed24e41c7a1cd98a3f2cfb4e0 and dial-in information will be provided directly to you. The live audio webcast will be accessible in the “Events” section of the Company’s Investor Relations website at https://investors.thevitacococompany.com. An archived replay of the webcast will be available shortly after the live event has concluded.

About The Vita Coco Company

The Vita Coco Company is a family of brands on a mission to reimagine what’s possible when brands deliver healthy, nutritious, and great tasting products that are better for consumers and better for the world. This includes its flagship coconut water brand Vita Coco, and Copra, a super-premium brand that specializes in Thai Nam Hom coconut water. The Company was co-founded in 2004 by Michael Kirban and Ira Liran and is a public benefit corporation and Certified B Corporation. Vita Coco, the principal brand within the Company’s portfolio, is the leading coconut water brand in the U.S. With electrolytes and nutrients, coconut water has become a top beverage choice among consumers after a workout, in smoothies, as a cocktail mixer, after a night out and more.

Contacts

Investor Relations:
ICR, Inc.
investors@thevitacococompany.com

Non-GAAP Financial Measures

In addition to disclosing results determined in accordance with U.S. GAAP, the Company also discloses certain non-GAAP results of operations, including, but not limited to, Adjusted EBITDA, and organic net sales growth, which include certain adjustments or exclude certain charges and gains that are described in the reconciliation table of U.S. GAAP to non-GAAP information provided at the end of this release. These non-GAAP measures are a key metric used by management and our board of directors to assess our financial performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company. In addition, we believe the presentation of these measures is useful to investors for period-to-period comparisons of results as the items described below in the reconciliation tables do not reflect ongoing operating performance.

These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces their usefulness as a comparative measure. Investors should not rely on any single financial measure when evaluating our business. This information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP. We recommend investors review the U.S. GAAP financial measures included in this earnings release. When viewed in conjunction with our U.S. GAAP results and the accompanying reconciliations, we believe these non-GAAP measures provide greater transparency and a more complete understanding of factors affecting our business than U.S. GAAP measures alone.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our future financial and operating performance, including our GAAP and non-GAAP guidance, our strategy, projected costs, tariffs, prospects, expectations, plans, objectives of management, supply chain predictions, customer and supplier relationships, expected impact of acquisitions, and expected net sales and category share growth.

The forward-looking statements in this release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond the Company’s control. These factors include, but are not limited to, those discussed under the caption “Risk Factors” in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission (“SEC”) as such factors may be updated from time to time and which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of our website at https://investors.thevitacococompany.com. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

Website Disclosure

We intend to use our websites, vitacoco.com and investors.thevitacococompany.com, as a means for disclosing material non-public information and for complying with the SEC’s Regulation FD and other disclosure obligations.

THE VITA COCO COMPANY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share data)
	September 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	151,995			$	196,873
Accounts receivable, net of allowance of $3,282 at September 30, 2026, and $2,660 at December 31, 2025		128,724				81,514
Inventory		111,296				111,468
Supplier advances, current		339				693
Derivative assets		1,794				732
Prepaid expenses and other current assets		39,536				30,160
Total current assets		433,684				421,440
Property and equipment, net		24,441				9,298
Goodwill		110,175				7,791
Intangible assets, net		107,116				—
Supplier advances, long-term		1,593				1,860
Deferred tax assets, net		6,627				6,623
Right-of-use assets, net		10,337				11,592
Other assets		2,169				2,714
Total assets	$	696,142			$	461,318
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	46,389			$	25,464
Accrued expenses and other current liabilities		126,632				89,461
Derivative liabilities		2,059				1,507
Total current liabilities		175,080				116,432
Deferred tax liability		24,875				160
Operating lease liability, long-term		12,119				13,087
Seller’s earn-out		55,100				—
Other long-term liabilities		240				97
Total liabilities	$	267,414			$	129,776
Stockholders’ equity:
Common stock, $0.01 par value; 500,000,000 shares authorized; 65,396,253 and 64,186,549 shares issued at September 30, 2026 and December 31, 2025, respectively; 57,202,356 and 57,082,173 shares outstanding at September 30, 2026 and December 31, 2025, respectively.		654				642
Additional paid-in capital		231,578				185,400
Retained earnings		342,956				228,014
Accumulated other comprehensive gain (loss)		(1,050	)			486
Treasury stock, 8,193,897 shares at cost as of September 30, 2026, and 7,104,376 as of December 31, 2025.		(145,410	)			(83,000	)
Total stockholders’ equity		428,728				331,542
Total liabilities and stockholders’ equity	$	696,142			$	461,318

THE VITA COCO COMPANY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except for share and per share data)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Net sales	$	243,825			$	182,313			$	639,744			$	481,993
Cost of goods sold		151,148				113,645				369,942				303,975
Gross profit		92,677				68,668				269,802				178,018
Operating expenses
Selling, general and administrative		47,226				40,745				127,629				105,680
Income from operations		45,451				27,923				142,173				72,338
Other income (expense)
Unrealized (loss) gain on derivative instruments		(2,083	)			2,391				511				6,275
Foreign currency loss		(887	)			(1,411	)			(2,432	)			(349	)
Interest income, net		1,231				1,776				5,252				4,794
Other (expense) income, net		(84	)			—				(77	)			155
Total other (expense) income		(1,823	)			2,756				3,254				10,875
Income before income taxes		43,628				30,679				145,427				83,213
Income tax expense		8,611				6,676				30,485				17,420
Net income	$	35,017			$	24,003			$	114,942			$	65,793
Net income attributable to The Vita Coco Company, Inc. per common share
Basic	$	0.61			$	0.42			$	2.01			$	1.16
Diluted	$	0.58			$	0.40			$	1.89			$	1.10
Weighted-average number of common shares outstanding
Basic		57,453,252				56,850,812				57,274,270				56,879,627
Diluted		60,831,632				59,878,602				60,786,462				59,832,067

THE VITA COCO COMPANY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands)
	Nine Months Ended September 30,
	2026				2025
Cash flows from operating activities:
Net income	$	114,942			$	65,793
Adjustments required to reconcile net income to cash flows from operating activities:
Depreciation and amortization		2,458				636
Amortization of debt issuance cost		14				11
Increase of provision for credit losses		187				1,300
Unrealized (gain) on derivative instruments		(511	)			(6,275	)
Stock-based compensation		11,338				8,123
Impairment loss on Runa assets		—				185
Noncash lease expense		1,242				1,052
Changes in operating assets and liabilities:
Accounts receivable		(42,801	)			(39,706	)
Inventory		33,259				(302	)
Prepaid expenses, net supplier advances, and other assets		(7,236	)			345
Accounts payable, accrued expenses, and other liabilities		39,050				19,907
Net cash provided by operating activities		151,942				51,069
Cash flows from investing activities:
Cash paid for property and equipment		(803	)			(4,921	)
Acquisition of Copra Inc., net of $8,340 cash acquired		(139,253	)			—
Net cash used in investing activities		(140,056	)			(4,921	)
Cash flows from financing activities:
Proceeds from exercise of stock awards		6,131				2,281
Cash paid on notes payable		(3	)			(8	)
Cash paid to acquire treasury stock		(62,410	)			(10,204	)
Net cash used in financing activities		(56,282	)			(7,931	)
Effects of exchange rate changes on cash and cash equivalents		(475	)			833
Net (decrease) increase in cash and cash equivalents		(44,871	)			39,050
Cash, cash equivalents and restricted cash at beginning of the period (1)		198,154				165,933
Cash, cash equivalents and restricted cash at end of the period (1)	$	153,283				204,983

¹ Includes $1,281 and $1,264 of restricted cash as of December 31, 2025 and 2024, respectively. Includes $1,288 and $1,278 of restricted cash as of September 30, 2026 and 2025, respectively, reported in other current assets on the condensed consolidated balance sheet.

During the nine months ended September 30, 2026, the Company issued common stock with a fair value of $35,000 and recognized contingent consideration with a fair value of $55,100 in connection with the acquisition of Copra. These transactions are reflected as noncash investing and financing activities.

RECONCILIATION FROM GAAP NET INCOME TO NON-GAAP ADJUSTED EBITDA
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
	(in thousands)								(in thousands)
Net income		35,017				24,003			$	114,942			$	65,793
Depreciation and amortization		1,493				228				2,458				636
Interest income, net		(1,231	)			(1,776	)			(5,252	)			(4,794	)
Income tax expense		8,611				6,676				30,485				17,420
EBITDA	$	43,890			$	29,131			$	142,633			$	79,055
Stock-based compensation (a)		3,122				2,975				11,338				8,123
Unrealized loss (gain) on derivative instruments (b)		2,083				(2,391	)			(511	)			(6,275	)
Foreign currency loss (b)		887				1,411				2,432				349
Acquisition-related costs (c)		3,174				—				3,174				—
Other adjustments (d)		—				1,264				—				2,886
Adjusted EBITDA	$	53,156			$	32,390			$	159,066			$	84,138

(a)	Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards and forfeitures. We adjusted for these charges to facilitate comparison from period to period.
(b)	Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.
(c)	Acquisition-related costs represent transaction, advisory, legal, accounting, valuation, and other professional fees incurred in connection with the acquisition of Copra.
(d)	The three and nine months ended September 30, 2025 included $0.6 million and $1.8 million, respectively, related to a one-time incentive program established in 2023 and measured based on full-year 2025 performance, and $0.4 million and $1.1 million, respectively, of overlapping rent expense associated with our new New York City office, and $0.2 million of impairment loss related to the sale of Runa. The three months ended September 30, 2025 also includes $0.1 million of provision for credit losses related to the partially recovered prepaid inventory from a supplier recorded in the first half of 2025 (refer to the Form 10-K and the Form 10-Q for the quarterly period ended June 30, 2025 for further details). The nine month period was partially offset by $0.1 million of partial recoveries of prepaid inventory from a supplier (refer to the Form 10-K for further details) and a $0.2 million gain from a sale of intellectual property.

RECONCILIATION FROM GAAP NET SALES GROWTH TO NON-GAAP ORGANIC NET SALES GROWTH
	Three Months Ended September 30, 2026			Nine Months Ended September 30, 2026
Net sales growth	33.7	%		32.7	%
Impact of Copra acquisition	16.0	%		6.0	%
Organic net sales growth	17.8	%		26.7	%

SUPPLEMENTAL INFORMATION

	NET SALES
	Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands)	2026			2025			2026			2025
Americas segment
Vita Coco Coconut Water	$	143,276		$	132,438		$	399,231		$	339,006
Private Label		46,495			14,360			97,795			50,242
Other		8,786			4,926			22,162			17,037
Subtotal	$	198,557		$	151,724		$	519,188		$	406,285
International segment
Vita Coco Coconut Water	$	34,363		$	21,939		$	88,645		$	54,998
Private Label		10,297			8,137			30,462			19,118
Other		608			513			1,449			1,592
Subtotal	$	45,268		$	30,589		$	120,556		$	75,708
Total net sales	$	243,825		$	182,313		$	639,744		$	481,993

	COST OF GOODS SOLD & GROSS PROFIT
	Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)	2026				2025				2026				2025
Cost of goods sold
Americas segment	$	122,824			$	93,859			$	293,240			$	255,062
International segment		28,324				19,786				76,702				48,913
Total cost of goods sold	$	151,148			$	113,645			$	369,942			$	303,975
Gross profit
Americas segment	$	75,732			$	57,866			$	225,948			$	151,224
International segment		16,945				10,802				43,854				26,794
Total gross profit	$	92,677			$	68,668			$	269,802			$	178,018
Gross margin
Americas segment		38.1	%			38.1	%			43.5	%			37.2	%
International segment		37.4	%			35.3	%			36.4	%			35.4	%
Consolidated		38.0	%			37.7	%			42.2	%			36.9	%

	VOLUME (CE)
	Percentage Change – Three Months Ended September 30, 2026 vs. 2025
	Americas segment			International segment			Total
Vita Coco Coconut Water	8.5	%		50.5	%		15.8	%
Private Label	109.9	%		23.1	%		76.7	%
Other	34.9	%		108.7	%		35.8	%
Subtotal	22.5	%		42.1	%		26.5	%
	Percentage Change – Nine Months Ended September 30, 2026 vs. 2025
	Americas segment			International segment			Total
Vita Coco Coconut Water	13.2	%		52.5	%		19.7	%
Private Label	63.4	%		48.8	%		58.9	%
Other	16.6	%		(14.2	)%		15.8	%
Subtotal	21.2	%		51.0	%		26.8	%

Note: A CE is a standard volume measure used by management which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil. We may have immaterial sales of raw materials at times that are treated as zero CEs for the purposes of these calculations.

• Introducing the industry’s first Industrial AI Agents at the Edge, providing a practical pathway to Physical AI
• Built on HPE Private Cloud AI, autonomous AI agents operate directly within industrial environments, continuously monitoring, reasoning, and optimizing operations in real time
• Addresses three key barriers to industrial AI adoption at scale: data sovereignty, cybersecurity and AI consumption costs

BERLIN, Oct. 22, 2026 (GLOBE NEWSWIRE) — Schneider Electric, a global energy technology leader, today announced a strategic collaboration with NVIDIA and HPE to accelerate the adoption of Physical AI across process and heavy industries.

While much of today’s Physical AI conversation is focused on robotics, humanoids and autonomous machines, process industries face a distinctly different challenge. Operators must manage complex, continuous operations where reliability, safety, cybersecurity and energy efficiency are critical to performance. Yet until now, there has been no clear blueprint for how Physical AI can be practically applied across these complex environments.

Schneider Electric, NVIDIA & HPE share a vision to bring AI closer to industrial operations, embedding intelligence directly within the environments where decisions are made and value is created. As an initial demonstration of this vision, the companies are today introducing Industrial AI Agents at the Edge.

The solution combines HPE Private Cloud AI, co-engineered with NVIDIA within the HPE AI Factory with NVIDIA portfolio Schneider Electric’s deep operational technology expertise to enable organizations to securely deploy and scale AI applications at the industrial edge, bringing real-time intelligence closer to critical operations while maintaining control over sensitive data, security and costs.

Many industrial organizations continue to face challenges when scaling AI across operational environments. Requirements around data governance, cybersecurity, operational performance and AI deployment can create barriers to broader adoption. By operating at the edge, the solution helps address three challenges that continue to limit industrial AI at scale:

• Data sovereignty. Critical operational data is often too valuable, sensitive or regulated to move beyond operational boundaries. HPE Private Cloud AI provides the secure foundation for Industrial AI Agents at the Edge, enabling organizations to deploy AI close to operations while maintaining control, security, and compliance.
• Cybersecurity. Increased connectivity can introduce additional risk across industrial and critical infrastructure environments. HPE Private Cloud AI reduces the attack surface by keeping and processing the data close to its source.
• AI consumption costs. As AI usage grows, cloud-based inference, data transfer and token-related costs can increase, creating challenges for organizations looking to scale AI across sites, assets and operations. Deploying AI at the edge with HPE Private Cloud AI can help reduce some of these costs while providing greater control over where and how AI workloads are executed.

Through Schneider Electric’s EcoStruxure Industrial Insights apps customers can deploy, manage and govern multiple Industrial AI Agents through a single environment, simplifying lifecycle management, security oversight and maintaining full control of critical operations and infrastructure.

The first Industrial AI Agents focus on operational technology monitoring, cybersecurity and energy optimization. Their practical application can already be seen in industrial environments with companies such as CMPC Chile.

Operational Technology Monitoring System in Production: CMPC

The foundation for this next step is already proven at CMPC Chile, part of Empresas CMPC S.A., one of Latin America’s largest pulp, paper and packaging producers. For the past three years, CMPC Chile has used Schneider Electric’s OTMS in production to monitor the health and availability of control systems across its continuous pulp and paper operations.

OTMS provides CMPC’s teams with a unified view of control systems, servers, workstations and switches, helping specialists identify emerging issues earlier, diagnose problems faster and establish clearer maintenance priorities. This proven deployment demonstrates the value of OTMS as a control-system monitoring solution and provides a strong operational foundation for the future introduction of Industrial AI Agents, with the potential to accelerate investigation and decision-making while keeping people in control of critical action.

The first three Industrial AI Agents at the edge

• OT Monitoring Agents: Combines real-time operational data, equipment configurations, process topology, alarms, maintenance history and engineering context to understand the physical state of industrial operations. The agents identify emerging issues, reasons about likely operational impacts, recommends or initiates corrective actions, and verifies that the intervention delivers the expected physical outcome.
• Cybersecurity Agents: Correlates network activity, control system behaviour, asset configurations, operational events and process context to detect abnormal conditions. The agents assess potential impacts on industrial operations, recommends or executes response measures, and validates that systems have returned to a secure and stable state.
• Energy Optimization Agents: Integrates process data, energy consumption patterns, equipment performance, operating conditions and production requirements to understand how energy is used across industrial operations. The agents identify optimization opportunities, recommends or implements adjustments, and verifies the resulting impact on energy efficiency, operational performance and sustainability outcomes.

“The next generation of industrial innovation will be driven by intelligence embedded directly into industrial operations,” said Gwenaelle Huet, Executive Vice President, Industrial Automation, Schneider Electric. “While much of today’s focus is on autonomous machines, we see a significant opportunity to apply Physical AI to the industrial systems that power the world’s critical industries. Together with NVIDIA and HPE, we are bringing together expertise in automation, AI and edge computing to help customers transform operational data into action, improving resilience, efficiency, cybersecurity and sustainability while laying the foundation for more autonomous industrial operations.”

“Industrial operations generate vast amounts of data, but turning that data into action remains one of industry’s biggest challenges. By combining NVIDIA Nemotron™ open AI models and HPE Private Cloud AI, a turnkey AI factory solution, with Schneider Electric’s industrial expertise and OTMS platform, Industrial AI Agents can monitor, reason and optimize operations in real time, accelerating the path to Physical AI for process industries,” commented Sri Kodali, Global Head of Developer Relations – Energy and Utilities at NVIDIA.

“Industrial organizations see real opportunities to use AI, and they want to be sure their sensitive data and critical systems will remain protected. Through our collaboration with NVIDIA and Schneider Electric, we’re helping customers use HPE Private Cloud AI to bring AI closer to where their data is generated and decisions are made. This gives customers a way to expand AI use across their facilities while maintaining the security, privacy and control their businesses require,” said Alexia Clements, SVP, Hybrid Cloud Solution Sales at HPE.

“For the past three years, OTMS has helped us improve visibility into the health and availability of our control systems. In continuous industrial operations, identifying issues early is critical to protecting production and avoiding costly disruption. Looking ahead, we see significant potential for AI Agents to build on this proven foundation, helping our specialists investigate issues faster and move more effectively from insight to action, while keeping people in control of critical decisions,” said Matías Jory, Digital & Process Manager, Industrial Operations Vice-Presidency, CMP.

Together, Schneider Electric, NVIDIA and HPE are creating the foundation for the next generation of industrial operations, where intelligent systems can continuously monitor, reason and optimize performance. Over time, these capabilities will help automate the automation, enabling safer, more efficient and increasingly autonomous operations across process industries.

Press contact: mediarelations@se.com

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability. The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world’s most sustainable companies. 

www.se.com

Learn more about Advancing Energy Tech on Schneider Electric Insights.

BRAMPTON, Ontario, Oct. 22, 2026 (GLOBE NEWSWIRE) — Loblaw Companies Limited (TSX: L) announced today that it will release its 2026 third quarter results on November 19, 2026, at approximately 6:30 a.m. (ET). The release will be followed by a conference call at 10:00 a.m. (ET), as well as an audio webcast.

To access via audio webcast please go to the “Investor” section of loblaw.ca and note that pre-registration will be available. Alternatively, please dial (647) 932-3411 or Toll-Free (800) 715-9871. Following the live event, the webcast will be archived and available to replay for 12 months.

About Loblaw Companies Limited

Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, health and beauty, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 corporate franchised and Associate-owned locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.

Loblaw’s purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; Joe Fresh® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand®, Farmer’s Market^TM, no name® and President’s Choice®.

For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw’s issuer profile at www.sedarplus.ca.

Media Enquiries, contact:

Scott Bonikowsky
Loblaw Companies Limited, Senior-Vice President Corporate Affairs and Communications
pr@loblaw.ca

Investors Enquiries, contact:

Roy MacDonald
Loblaw Companies Limited, Vice President Investor Relations
investor@loblaw.ca

BETHESDA, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ:LQDT), the leading global provider of e-commerce marketplaces and software solutions powering the circular economy, today announced that it expects to report its fourth quarter and fiscal year 2026 results prior to market open on Thursday, November 19, 2026. Bill Angrick, Chairman and CEO, and Jorge Celaya, EVP and CFO, will then host a conference call to review the results at 10:30 AM Eastern Time.

To participate in the conference call, please register here to receive the dial-in number and unique conference pin. A listen-only live webcast of the conference call will also be provided on the Company’s investor relations site.

An archive of the webcast will be available on the Company’s website until November 19, 2027. To listen to the replay, visit the Liquidity Services investor relations site. The replay will be available starting at 1:30 PM Eastern Time on the day of the call.

About Liquidity Services
Liquidity Services (NASDAQ: LQDT) operates the world’s largest B2B e-commerce marketplace platform for surplus assets with over $15 billion in completed transactions to more than six million qualified buyers and 15,000 corporate and government sellers worldwide. The company supports its clients’ sustainability efforts by helping them extend the life of assets, prevent unnecessary waste and carbon emissions, and reduce the number of products headed to landfills.

Contact:
Liquidity Services
Investor Relations
InvestorRelations@LiquidityServices.com

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s Net principal loss rate and Delinquency rate for the periods indicated:

	For the month ended September 30, 2026				For the three months ended September 30, 2026
	(dollars in millions)
End-of-period credit card and other loans	$	18,850			$	18,850
Average credit card and other loans	$	18,740			$	18,591
Year-over-year change in average credit card and other loans		6.4	%			5.7	%
Net principal losses	$	92			$	300
Net principal loss rate		5.99	%			6.40	%

	As of September 30, 2026				As of September 30, 2025
	(dollars in millions)
30 days + delinquencies – principal	$	923			$	963
Period ended credit card and other loans – principal	$	16,584			$	15,928
Delinquency rate		5.57	%			6.04	%

About Bread Financial^®
Bread Financial^®(NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel and entertainment, specialty apparel, health and beauty, jewelry, sporting goods, technology and electronics, as well as home and furniture through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.​

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements give our expectations or forecasts of future events and can generally be identified by the use of words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “project,” “plan,” “likely,” “may,” “should” or other words or phrases of similar import. Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding, and the guidance we give with respect to, our anticipated operating or financial results, future financial performance and outlook, future dividend declarations, and future economic conditions.

We believe that our expectations are based on reasonable assumptions. Forward-looking statements, however, are subject to a number of risks and uncertainties that are difficult to predict and, in many cases, beyond our control. Accordingly, our actual results could differ materially from the projections, anticipated results or other expectations expressed in this release, and no assurances can be given that our expectations will prove to have been correct. Factors that could cause the outcomes to differ materially include, but are not limited to, the following: macroeconomic conditions, including inflation, interest rates, labor market conditions, financial and capital market conditions, recessionary pressures or concerns over a prolonged economic slowdown, and the related impact on consumer spending behavior, payments, debt levels, savings rates and other behaviors; domestic and international political events and conditions, including significant shifts in trade policy, such as changes to, or the imposition of, tariffs and/or trade barriers and consequently any economic impacts, volatility, uncertainty and geopolitical instability resulting therefrom, as well as ongoing wars and military conflicts, and international tensions or hostilities; local or global public health issues, climate-related events, impacts to the power grid, and natural disasters; future credit performance, including the level of future delinquency and charge-off rates; loss of, or reduction in demand for services and/or products from, significant brand partners or customers in the highly competitive markets in which we operate, including competition from new and non-traditional competitors, such as financial technology companies, and with respect to new products, services and technologies, such as the emergence or increase in popularity of agentic commerce, digital payment platforms and currencies and other alternative payment and deposit solutions; the concentration of our business in U.S. consumer credit; inaccuracies in the models and estimates on which we rely, including our credit risk management models and the amount of our Allowance for credit losses; the inability to realize the intended benefits of acquisitions, dispositions and other strategic initiatives; our level of indebtedness and ability to access financial or capital markets; pending and future federal and state legislation, executive action, regulation, supervisory guidance, and regulatory and legal actions, including, but not limited to, those related to financial regulatory reform and consumer financial services practices, as well as any such actions that would place limits on credit card interest rates or late fees, interchange fees or other charges; failures or breaches in our operational or security systems, including as a result of cyberattacks, unanticipated impacts from technology modernization projects or otherwise; and any liability or other adverse impacts arising out of or related to the spinoff of our former LoyaltyOne segment or the bankruptcy filings of Loyalty Ventures Inc. (LVI) and certain of its subsidiaries, including the pending litigation against us in connection with the spinoff. The foregoing factors, along with other risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements, are described in greater detail under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the most recently ended fiscal year, which may be updated in Item 1A of, or elsewhere in, our Quarterly Reports on Form 10-Q filed for periods subsequent to such Form 10-K. Our forward-looking statements speak only as of the date made, and we undertake no obligation, other than as required by applicable law, to update or revise any forward-looking statements, whether as a result of new information, subsequent events, anticipated or unanticipated circumstances or otherwise.

Contacts   
Brian Vereb — Investor Relations   
Brian.Vereb@breadfinancial.com   
   
Susan Haugen — Investor Relations   
Susan.Haugen@breadfinancial.com   
   
Rachel Stultz — Media   
Rachel.Stultz@breadfinancial.com   

Increases full year DEPS guidance

SARASOTA, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) reported financial results for the third quarter ended September 30, 2026.

Third quarter 2026 highlights

• Revenue increased 8% to $2.17 billion; organic revenue was +7% and acquisition contribution was +1%
• GAAP net earnings increased 22% to $485 million; adjusted net earnings increased 5% to $586 million
• Adjusted EBITDA increased 7% to $864 million
• GAAP DEPS increased 33% to $4.88; adjusted DEPS increased 15% to $5.89

“Roper delivered another solid quarter, with 8% total revenue growth, 7% organic revenue growth, 7% EBITDA growth, and 15% adjusted DEPS growth. During the quarter, we deployed $436 million toward three bolt-on acquisitions for our iPipeline, Procare, and Strata businesses, and we received $1.2 billion in proceeds from Indicor’s sale of its instrumentation businesses,” said Neil Hunn, Roper Technologies’ President and CEO.

“This quarter, our businesses again brought several AI launches to market, highlighted by PowerPlan, Strata, and Vertafore. We are embedding agentic solutions directly into the workflows our customers rely on every day, and we are also evolving how we build, with smaller teams closer to customers and increasingly agentic development processes. Given the depth of our customer relationships, our proprietary and unique data sets, and our embedded position inside mission-critical workflows, we are well positioned to create value for customers with AI. We are laser focused on scaling adoption while continuing to accelerate innovation.”

“Driven by third quarter adjusted DEPS that exceeded our expectations, we are raising our full year adjusted DEPS guidance. With more than $6 billion of capital deployment capacity, we will continue allocating capital with discipline to drive free cash flow per share compounding for our shareholders,” concluded Mr. Hunn.

Increasing 2026 guidance

Roper now expects full year 2026 adjusted DEPS of $22.35 – $22.40, compared to previous guidance of $22.15 – $22.30.

For the fourth quarter of 2026, the Company expects adjusted DEPS of $5.95 – $6.00.

The Company’s guidance excludes the impact of unannounced future acquisitions or divestitures, proceeds from Indicor’s pending divestiture of its Cornell Pump and Roper Pump businesses, as well as potential share repurchases.

Conference call to be held at 8:00 AM (ET) today

A conference call to discuss these results has been scheduled for 8:00 AM ET on Thursday, October 22, 2026. The call can be accessed via webcast or by dialing +1 800-836-8184 (US/Canada) or +1 646-357-8785, using conference call ID 80101. Webcast information and conference call materials will be made available in the Investors section of Roper’s website (www.ropertech.com) prior to the start of the call. The webcast can also be accessed directly by using the following URL https://event.webcast. Telephonic replays will be available for up to two weeks and can be accessed by dialing +1 646-517-4150 with access code 80101 #.

Use of non-GAAP financial information

The Company supplements its consolidated financial statements presented on a GAAP basis with certain non-GAAP financial information to provide investors with greater insight, increase transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Reconciliation of non-GAAP measures to their most directly comparable GAAP measures are included in the accompanying financial schedules or tables. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP, and the financial results prepared in accordance with GAAP and reconciliations from these results should be carefully evaluated.

Minority interest

Following the sale of a majority stake in its industrial businesses to CD&R, Roper holds a minority interest in Indicor. The fair value of Roper’s equity investment in Indicor is updated on a quarterly basis and reported as “equity investment (gain) loss, net.” Roper makes non-GAAP adjustments for the impacts associated with this investment.

Table 1: Revenue and adjusted EBITDA reconciliation ($M)
	Q3 2025				Q3 2026				V %
GAAP revenue	$	2,017			$	2,172			8	%
Components of revenue growth
Organic									7	%
Acquisitions									1	%
Foreign exchange									—	%
Total revenue growth									8	%
Adjusted EBITDA reconciliation
GAAP net earnings	$	398			$	485
Taxes		100				87
Interest expense		90				107
Depreciation		10				10
Amortization		221				225
EBITDA	$	819			$	914			12	%
Transaction-related expenses for completed acquisitions		4				6
Financial impacts associated with minority investments		(13	)			(56	)	A
Adjusted EBITDA	$	810			$	864			7	%
Adjusted EBITDA margin		40.2	%			39.8	%		(40 bps)

Table 2: Adjusted net earnings reconciliation ($M)
	Q3 2025				Q3 2026				V %
GAAP net earnings	$	398			$	485			22	%
Transaction-related expenses for completed acquisitions		3				5
Financial impacts associated with minority investments		(10	)			(71	)	A
Amortization of acquisition-related intangible assets		165				167		B
Adjusted net earnings C	$	557			$	586			5	%

Table 3: Adjusted DEPS reconciliation
	Q3 2025				Q3 2026				V %
GAAP DEPS	$	3.68			$	4.88			33	%
Transaction-related expenses for completed acquisitions		0.03				0.05
Financial impacts associated with minority investments		(0.09	)			(0.71	)	A
Amortization of acquisition-related intangible assets		1.53				1.68		B
Adjusted DEPS C	$	5.14			$	5.89			15	%

Table 4: Forecasted adjusted DEPS reconciliation
	Q4 2026						FY 2026 D
	Low end			High end			Low end				High end
GAAP DEPS E	$	4.27		$	4.32		$	25.60			$	25.65
YTD transaction-related expenses for completed acquisitions		—			—			0.05				0.05
YTD financial impacts associated with the minority investment in Indicor A	TBD			TBD				(9.86	)			(9.86	)
Amortization of acquisition-related intangible assets B		1.68			1.68			6.56				6.56
Adjusted DEPS C	$	5.95		$	6.00		$	22.35			$	22.40

Footnotes:

A.	Adjustments related to the financial impacts associated with the minority investment in Indicor as shown below ($M, except per share data). Forecasted results do not include any future impacts associated with our minority investment in Indicor, as these future impacts cannot be reasonably predicted. These impacts will be excluded from all non-GAAP results in future periods.
		Q3 2026A						Q4 2026E			FY 2026E			YTD 2026
	Pretax	$	(56	)				TBD			TBD			$	(1,059	)
	After-tax	$	(71	)				TBD			TBD			$	(996	)
	Per share	$	(0.71	)				TBD			TBD			$	(9.86	)
B.	Actual results and forecast of estimated amortization of acquisition-related intangible assets as shown below ($M, except per share data).
		Q3 2026A						Q4 2026E			FY 2026E
	Pretax	$	212				$	212		$	839
	After-tax	$	167				$	168		$	663
	Per share	$	1.68				$	1.68		$	6.56
C.	All actual and forecasted non-GAAP adjustments are taxed at 21% with the exception of the financial impacts associated with minority investments.
D.	Full-year 2026 DEPS guidance will not equal the sum of the quarters due primarily to the impact of share repurchases on quarterly versus full-year weighted-average diluted shares outstanding.
E.	Forecasted GAAP DEPS do not include any future impacts associated with our minority investment in Indicor. These impacts will be excluded from all non-GAAP results in future periods.

Note: Numbers may not foot due to rounding.

About Roper Technologies

Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company’s website at www.ropertech.com.

Contact information:
Investor Relations
941-556-2601
investor-relations@ropertech.com

The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as “anticipate,” “estimate,” “plans,” “expects,” “projects,” “should,” “will,” “believes,” “intends” and similar words and phrases. These statements reflect management’s current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, acquired businesses, including obtaining any required regulatory approvals with respect thereto, and our ability to develop, deploy, and use artificial intelligence in our platforms and offerings. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, including risks related to labor shortages and volatile interest rates, changes in foreign exchange rates, risks related to changing U.S. and foreign trade policies, including increased trade restrictions or tariffs, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, including as a result of inflation and potential supply chain constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

Roper Technologies, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(Amounts in millions)
	September 30, 2026				December 31, 2025
ASSETS:
Cash and cash equivalents	$	311.0			$	297.4
Accounts receivable, net		981.1				1,001.0
Inventories, net		153.3				141.7
Income taxes receivable		56.7				128.2
Unbilled receivables		152.6				124.0
Prepaid expenses and other current assets		291.6				235.8
Total current assets		1,946.3				1,928.1
Property, plant and equipment, net		158.4				156.9
Goodwill		21,555.0				21,341.2
Other intangible assets, net		9,455.7				9,764.2
Deferred taxes		69.0				73.3
Equity investment		577.0				796.3
Other assets		576.9				517.0
Total assets	$	34,338.3			$	34,577.0
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Accounts payable	$	176.3			$	150.3
Accrued compensation		288.9				293.0
Deferred revenue		1,889.3				1,906.8
Other accrued liabilities		590.1				642.3
Income taxes payable		211.5				28.0
Current portion of long-term debt, net		1,415.1				705.2
Total current liabilities		4,571.2				3,725.6
Long-term debt, net of current portion		8,304.6				8,595.8
Deferred taxes		1,785.2				1,883.1
Other liabilities		504.7				491.0
Total liabilities		15,165.7				14,695.5
Common stock, 350.0 shares authorized; 109.5 shares issued and 99.0 outstanding at September 30, 2026 and 109.3 shares issued and 106.6 outstanding at December 31, 2025		1.1				1.1
Additional paid-in capital		3,473.3				3,292.2
Retained earnings		19,091.2				17,205.7
Accumulated other comprehensive loss		(138.2	)			(101.4	)
Treasury stock, 10.5 shares at September 30, 2026 and 2.7 shares at December 31, 2025		(3,254.8	)			(516.1	)
Total stockholders’ equity		19,172.6				19,881.5
Total liabilities and stockholders’ equity	$	34,338.3			$	34,577.0

Roper Technologies, Inc.
Condensed Consolidated Statements of Earnings (unaudited)
(Amounts in millions, except per share data)
	Three months ended September 30,								Nine months ended September 30,
		2026				2025				2026				2025
Net revenues	$	2,171.8			$	2,017.5			$	6,376.0			$	5,843.9
Cost of sales		649.2				614.5				1,929.4				1,801.8
Gross profit		1,522.6				1,403.0				4,446.6				4,042.1
Selling, general and administrative expenses		899.4				830.0				2,669.1				2,395.0
Income from operations		623.2				573.0				1,777.5				1,647.1
Interest expense, net		106.7				89.7				317.4				231.7
Equity investment (gain) loss, net		(56.2	)			(12.9	)			(1,058.7	)			14.9
Other (income) expense, net		0.6				(2.0	)			3.7				(1.0	)
Earnings before income taxes		572.1				498.2				2,515.1				1,401.5
Income taxes		87.4				99.7				353.0				293.6
Net earnings	$	484.7			$	398.5			$	2,162.1			$	1,107.9
Net earnings per share:
Basic	$	4.90			$	3.70			$	21.36			$	10.31
Diluted	$	4.88			$	3.68			$	21.30			$	10.23
Weighted average common shares outstanding:
Basic		98.9				107.6				101.2				107.5
Diluted		99.4				108.4				101.5				108.3

Roper Technologies, Inc.
Selected Segment Financial Data (unaudited)
(Amounts in millions; percentages of net revenues)
	Three months ended September 30,												Nine months ended September 30,
		2026						2025						2026						2025
	Amount			%			Amount			%			Amount			%			Amount			%
Net revenues:
Application Software	$	1,239.7					$	1,161.0					$	3,612.0					$	3,324.1
Network Software		446.1						413.4						1,304.6						1,174.7
Technology Enabled Products		486.0						443.1						1,459.4						1,345.1
Total	$	2,171.8					$	2,017.5					$	6,376.0					$	5,843.9
Gross profit:
Application Software	$	865.5		69.8	%		$	801.0		69.0	%		$	2,511.8		69.5	%		$	2,275.1		68.4	%
Network Software		378.0		84.7	%			346.9		83.9	%			1,101.8		84.5	%			983.3		83.7	%
Technology Enabled Products		279.1		57.4	%			255.1		57.6	%			833.0		57.1	%			783.7		58.3	%
Total	$	1,522.6		70.1	%		$	1,403.0		69.5	%		$	4,446.6		69.7	%		$	4,042.1		69.2	%
Operating profit*:
Application Software	$	357.6		28.8	%		$	323.0		27.8	%		$	1,000.8		27.7	%		$	894.4		26.9	%
Network Software		189.6		42.5	%			178.1		43.1	%			540.0		41.4	%			514.1		43.8	%
Technology Enabled Products		160.7		33.1	%			150.2		33.9	%			480.8		32.9	%			467.9		34.8	%
Total	$	707.9		32.6	%		$	651.3		32.3	%		$	2,021.6		31.7	%		$	1,876.4		32.1	%
* Segment operating profit is before unallocated corporate general and administrative expenses and enterprise-wide stock-based compensation. These expenses were $84.7 and $78.3 for the three months ended September 30, 2026 and 2025, respectively, and $244.1 and $229.3 for the nine months ended September 30, 2026 and 2025, respectively.

Roper Technologies, Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(Amounts in millions)
	Nine months ended September 30,
		2026				2025
Cash flows from operating activities:
Net earnings	$	2,162.1			$	1,107.9
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property, plant and equipment		30.4				29.9
Amortization of intangible assets		666.3				638.0
Amortization of deferred financing costs		9.3				8.6
Non-cash stock compensation		163.9				128.7
Equity investment (gain) loss, net		(1,058.7	)			14.9
Income tax provision		353.0				293.6
Changes in operating assets and liabilities, net of acquired businesses:
Accounts receivable		22.9				(0.5	)
Unbilled receivables		(28.2	)			(7.2	)
Inventories		(12.6	)			(18.2	)
Prepaid expenses and other current assets		(48.7	)			(27.9	)
Accounts payable		26.2				13.2
Other accrued liabilities		(57.2	)			(48.9	)
Deferred revenue		(36.9	)			28.5
Cash taxes paid for gain on disposal of equity investment		—				(30.2	)
Cash income taxes paid, excluding tax associated with gain on disposal of equity investment		(283.7	)			(307.6	)
Other, net		(25.9	)			(20.5	)
Cash provided by operating activities		1,882.2				1,802.3
Cash flows from (used in) investing activities:
Acquisitions of businesses, net of cash acquired		(463.2	)			(3,280.4	)
Capital expenditures		(35.4	)			(37.6	)
Capitalized software expenditures		(46.8	)			(42.8	)
Distributions from equity investment		6.7				5.1
Proceeds from Indicor transaction		1,239.2				—
Cash receipts on beneficial interest in sold receivables		15.2				—
Other, net		0.3				1.7
Cash provided by (used in) investing activities		716.0				(3,354.0	)
Cash flows from (used in) financing activities:
Proceeds from senior notes		—				2,000.0
Payments of senior notes		—				(700.0	)
Borrowings under revolving credit facility, net		400.0				585.0
Debt issuance costs		(3.9	)			(19.5	)
Cash dividends to stockholders		(281.4	)			(266.0	)
Repurchases of common stock		(2,726.7	)			—
Proceeds from stock-based compensation, net		19.3				79.4
Treasury stock sales under employee stock purchase plan		12.7				17.4
Other, net		9.1				(42.0	)
Cash provided by (used in) financing activities		(2,570.9	)			1,654.3
Effect of exchange rate changes on cash		(13.7	)			29.2
Net increase in cash and cash equivalents		13.6				131.8
Cash and cash equivalents, beginning of period		297.4				188.2
Cash and cash equivalents, end of period	$	311.0			$	320.0

The renewal will support more personalized and rewarding experiences for Sephora customers and Beauty Insider members

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial^® (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, today announced a long-term renewal of its credit and loyalty program agreement with Sephora, one of the world’s leading prestige beauty retailers.

The renewal agreement reflects a shared commitment to delivering value for Sephora customers. Building on years of strong collaboration, Bread Financial and Sephora will continue to deepen the connection between Sephora’s branded credit and its Beauty Insider loyalty program, creating more personalized, synergistic and rewarding experiences across the customer journey.

“Sephora is a meaningful partner for Bread Financial, and this renewal reflects the deeply integrated partnership that has shaped our work together,” said Dennis McCarthy, executive vice president and chief revenue officer, Bread Financial. “Through our combined credit and signature loyalty programs, we are excited to play a role in enabling Sephora customers to be inspired by their unique beauty. We’re proud to work alongside Sephora to deliver experiences that feel personalized and rewarding in any channel customers choose to shop. We look forward to continuing to help Sephora enhance customer engagement and bring even greater value to Beauty Insider members.”

Under terms of the renewal agreement, Bread Financial and Sephora will continue advancing Sephora’s credit and loyalty offerings through enhanced personalization, innovative marketing strategies and seamless experiences across channels. Supported by ongoing investments in analytics, digital capabilities and customer insights, the program will deliver more relevant and rewarding experiences that deepen engagement with Beauty Insider members, strengthen brand affinity and support Sephora’s commitment to exceeding evolving customer expectations.

“At Sephora, we’re constantly looking for ways to deepen our relationships with our community and elevate the value of being a Beauty Insider member,” said Emeline Berlind, Senior Vice President, GM, Loyalty at Sephora. “Our longstanding partnership with Bread Financial has enabled us to build on the strong foundation and continue to create rewarding, personalized experiences for our clients. We’re excited to keep innovating alongside a partner who shares our commitment to putting customers first, and we look forward to shaping what’s next for the loyalty and credit experiences our community values most.”

About Bread Financial^®
Bread Financial^® (NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel & entertainment, health & beauty, technology, electronics, jewelry, home and specialty apparel through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

About Sephora
Sephora is the world’s leading global prestige beauty retail brand. With 55,000 passionate employees operating in 37 markets, Sephora connects customers and beauty brands within the world’s most trusted and dynamic beauty community. We serve a highly engaged community of hundreds of millions of beauty followers across our global omnichannel network of more than 3,400 stores and iconic flagships, and our e-commerce and digital platforms, offering personalized and immersive seamless experiences across every touchpoint. With our curation of close to 500 brands and our own label, Sephora Collection, we offer the most unique and diverse range of prestige beauty products, tailored to our customers’ needs from fragrance to make-up, haircare, skincare and beyond, as we constantly reimagine the world of prestige beauty.

Since our inception in 1969 in Limoges, France, and as part of the LVMH Group since 1997, we have been disrupting the prestige beauty retail industry. Today, we continue to break with convention to drive our mission: champion a world of inspiration and inclusion where everyone can celebrate their beauty.

Contacts 
Brian Vereb — Investor Relations 
Brian.Vereb@breadfinancial.com

Susan Haugen — Investor Relations 
Susan.Haugen@breadfinancial.com 

Rachel Stultz — Media 
Rachel.Stultz@breadfinancial.com 

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial^® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving solutions, today announced its third quarter 2026 financial results. All earnings-related materials are now available at the company’s investor relations website, here. 

Bread Financial President and Chief Executive Officer Ralph Andretta and Chief Financial Officer Perry Beberman will host a conference call at 8:30 a.m. ET today to discuss results. A link to the conference call will be available at the company’s investor relations website, and a replay will also be available there following the call. 

About Bread Financial^® 
Bread Financial^® (NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel & entertainment, health & beauty, technology, electronics, jewelry, home and specialty apparel through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn. 

Contacts 
Brian Vereb — Investor Relations 
Brian.Vereb@breadfinancial.com 

Susan Haugen — Investor Relations 
Susan.Haugen@breadfinancial.com 

Rachel Stultz — Media 
Rachel.Stultz@breadfinancial.com 

ATLANTA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Wisconsin-based transportation and logistics provider WEL Companies is using Descartes’ broker transportation management system (TMS) integrated with CARRIER1 Vault to move customers’ goods using its own trucks and to arrange shipments with other trucking companies in its for-hire network. The combined solution helps WEL’s freight brokers manage the shipment lifecycle with the Descartes solution while exchanging load information, status updates and delivery documents with the carriers and drivers moving the freight.

“The Descartes and CARRIER1 collaboration lets WEL automate communication and shipment data across our brokerage, our assets, and our for-hire carrier network, without our brokers ever leaving their TMS,” said Eric Lenze, EVP at WEL Companies. “That means a faster shipment lifecycle and a better experience for our customers.”

Descartes’ cloud-based broker TMS helps freight brokers and third-party logistics providers manage order entry, load coverage, carrier acceptance, dispatching and carrier communications. CARRIER1 Vault extends these workflows to trusted carriers and drivers through digital tendering, shipment tracking, communication and document exchange. As a load moves, carrier assignments, driver and equipment details, status updates and documents such as rate confirmations, bills of lading and proof of delivery can flow back to the corresponding load in the Descartes solution. The integration also supports carrier, driver and equipment verification, helping brokers reduce manual data entry and the need to piece together information from emails, spreadsheets and phone calls.

“Brokers need the systems that they already use to do more for them,” said Travis Rhyan, CEO of CARRIER1. “Connecting Vault with Descartes’ TMS brings the broker, carrier and driver into the same flow of information. The broker stays in their Descartes solution, the carrier gets what they need to move the load, and the information comes back without someone having to chase it down manually.”

“We’re pleased to help WEL Companies simplify brokerage operations by connecting more of the shipment lifecycle back into Descartes’ TMS through our integrated solution,” said Andrew Wimer, Associate General Manager at Descartes. “Our integration strategy gives brokers access to specialized capabilities while keeping Descartes’ TMS at the center of their operations. By collaborating with CARRIER1, we’re extending that approach to the carriers and drivers moving the freight, so brokers can spend less time gathering updates and documents and more time managing exceptions and serving customers.”

Learn more about Descartes’ transportation management solutions.

About WEL Companies

WEL Companies is a family-owned transportation, logistics and warehousing company headquartered in De Pere, Wisconsin. Founded in 1975, WEL provides refrigerated truckload and less-than-truckload transportation, integrated logistics and warehousing services. Learn more at www.welcompanies.com.

About CARRIER1

CARRIER1 connects freight brokers, carriers and drivers through technology designed to simplify the work surrounding a load. Its Vault platform integrates with existing transportation management systems to support carrier engagement, verification, shipment execution and document exchange. Learn more at www.carrier1.com.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack                                                                     
Tel: 226-750-8050                                 
cstrohack@descartes.com  

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ transportation management solution offerings and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

• BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancer
• The global Phase 3 ROSETTA Breast-01 trial will evolve to evaluate pumitamig in combination with sacituzumab govitecan, a TROP2-directed antibody-drug conjugate, reflecting the new standard of care in first-line treatment of metastatic triple-negative breast cancer
• This will be the first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate

MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate (“ADC”) sacituzumab govitecan (Trodelvy^®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (“TNBC”). Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb (“BMS”).

ROSETTA Breast-01 is a global, double-blinded Phase 3 clinical trial (NCT07173751) currently evaluating pumitamig in combination with chemotherapy versus chemotherapy in patients with locally advanced or metastatic PD-L1 low or negative TNBC (CPS < 10), initiated based on positive results from a global Phase 2 trial. In line with the evolving treatment landscape in this indication, BioNTech and BMS plan to adapt ROSETTA Breast-01 replacing chemotherapy with sacituzumab govitecan, pending regulatory authority approval, to ensure that patients are receiving the latest standard of care treatment.

Under the terms of the agreement, BioNTech will continue to sponsor and lead the ROSETTA Breast-01 trial. Gilead will supply sacituzumab govitecan for the combination trial.

“When the ROSETTA Breast-01 trial was initiated, chemotherapy was the only option for patients with PD‑L1 negative advanced TNBC. While chemotherapy remains a standard first-line option, TROP2-directed ADCs like sacituzumab govitecan are quickly becoming the new global standard of care. I am excited to evaluate the combination of pumitamig and sacituzumab govitecan in the ROSETTA Breast-01 trial to potentially further amplify the already meaningful improvement in patient outcomes that sacituzumab govitecan has demonstrated over chemotherapy,” said Peter Schmid, M.D., Ph.D., Lead Investigator and Director of the Breast Cancer Centre at St. Bartholomew’s Hospital.

Pumitamig is currently being investigated in seven ongoing global Phase 3 trials and 10+ Phase 2 novel-novel combination trials. ROSETTA Breast-01 will be the first global Phase 3 trial of pumitamig in combination with an ADC. BioNTech and Bristol Myers Squibb plan to evaluate the full potential of pumitamig in additional Phase 3 novel combination trials in multiple solid tumors, leveraging their broad oncology pipelines and exploring other potential additional collaborations.

“We aim to maximize potential benefit for patients with triple-negative breast cancer. Adapting ROSETTA Breast-01 to reflect the evolving standard of care gives the trial the best chance to inform clinical practice and, ultimately, treatment decisions for patients,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “Combining pumitamig as a potential backbone with complementary modalities such as ADCs is central to our therapeutic approach. Sacituzumab govitecan has advanced first‑line treatment of triple-negative breast cancer. By combining pumitamig and sacituzumab govitecan, we aim to determine whether this approach can further improve outcomes of patients.”

The use of pumitamig and sacituzumab govitecan in patients with first-line PD-L1 negative metastatic TNBC is investigational, and the safety and efficacy of this combination has not been established.

About Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), which is defined by a lack of hormone receptors (estrogen or progesterone) and HER2 protein, accounts for about 10-15% of all invasive breast cancer cases.¹ It is an aggressive type of breast cancer that tends to grow and spread faster and has a worse prognosis compared to other breast cancer types. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. The 5-year survival rate for patients with metastatic TNBC is only 15%, emphasizing the need for new treatment options.¹

About Pumitamig
Pumitamig is an investigational bispecific immunomodulator, jointly developed by BioNTech and BMS, designed to cooperatively bind to PD-L1 and VEGF-A. It is aimed at restoring the immune system’s ability to recognize and destroy tumor cells while simultaneously cutting off the blood and oxygen supply that feeds tumor cells (anti-angiogenesis effect), preventing them from growing and proliferating. By anchoring to PD-L1 receptors on tumor cells, we believe pumitamig localizes VEGF-A blockade within the tumor microenvironment, potentially enhancing antitumor activity while minimizing systemic exposure.

More than 4,000 patients have been treated with pumitamig in clinical trials to date. Seven global Phase 3 trials with registrational potential are currently ongoing, evaluating pumitamig plus chemotherapy compared to standard of care treatments, in first-line small cell lung cancer (ROSETTA Lung-01, NCT06712355); first-line non-small cell lung cancer (ROSETTA Lung-02, NCT06712316); unresectable stage III non-small cell lung cancer (ROSETTA Lung-201, NCT07361497); first-line advanced PD-L1 ≥ 50% non-small cell lung cancer (ROSETTA Lung-202, NCT07361510); first-line triple-negative breast cancer (ROSETTA Breast-01, NCT07173751); first-line microsatellite stable colorectal cancer (ROSETTA CRC-203, NCT07221357); and first-line gastric cancer (ROSETTA Gastric-204, NCT07221149). Pumitamig is also being explored in 10+ novel-novel combination trials with ADCs and other novel modalities, with the aim of expanding its role across tumor types and identifying additional pivotal opportunities.

About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s collaboration with Bristol Myers Squibb (BMS); BioNTech’s collaboration with Gilead; BioNTech and BMS’s ability to successfully co-develop and co-commercialize pumitamig (also known as BNT327 or BMS986545), if approved; the rate and degree of market acceptance of pumitamig, if approved; the initiation, timing, progress, and results of BioNTech’s research and development programs, including BioNTech’s current and future clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations, including expectations regarding the potential indications in which pumitamig may be approved, if at all; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; and discussions with regulatory agencies. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the impact of tariffs and escalations in trade policy; competition related to BioNTech’s product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s product candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

BioNTech
Media Relations
Jasmina Alatovic
Media@biontech.de

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

1 American Cancer Society. Triple-Negative Breast Cancer. https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html. Accessed October 15, 2026.